Return to Home [X]

Exciting News: Introducing the New Essential Evidence Plus!

We are thrilled to announce that a brand-new version of Essential Evidence Plus is on its way! Mark your calendars for the launch date, September 11th, as we are introducing a modern, mobile-first application that will revolutionize your experience. With this update, accessing our valuable content will be easier and more convenient than ever before.

What to Expect from the New Essential Evidence Plus:

  1. Modern Mobile-First Experience: Our new application has been meticulously designed with a mobile-first approach. No matter what device you're using, whether it's a smartphone, tablet, or desktop, you'll enjoy a seamless and intuitive user experience.
  2. Enhanced Accessibility: We understand the importance of accessing content from anywhere, at any time. The new Essential Evidence Plus will provide you with the flexibility to explore our extensive collection of evidence-based resources on the go, making it easier to stay up to date with the latest medical knowledge and interactive tools.
  3. Improved User Interface: We have revamped our user interface to ensure effortless navigation and a visually appealing experience. Finding the information, you need will be quicker and more intuitive, saving you valuable time and effort.

Essential Evidence Plus will be available to users during this transition. However, please note that ability to create new trial and individual subscriptions will not be available from September 8th to September 11th 7:00 AM EST. During this period, we will be working diligently to transfer our existing system to the upgraded platform, ensuring a seamless transition for all users.

We apologize for any inconvenience caused by this temporary interruption. Rest assured, our team is committed to bringing you a superior user experience, and we appreciate your patience and understanding during this time.

Stay Tuned for the New Essential Evidence Plus!

We are counting down the days until September 11th when the new Essential Evidence Plus will be available for you to explore. Get ready to unlock a wealth of evidence-based resources that empower you in your medical decision-making process.

Thank you for your continued support, and we look forward to delivering an exceptional experience with the all-new Essential Evidence Plus!

Essential Evidence Plus

Browse Databases and Tools

Sort by Show per page
  • Benzodiazepines for delirium
    Cochrane Systematic Reviews, 7-Oct-2009
  • Benzodiazepines for neuroleptic‐induced acute akathisia
    Cochrane Systematic Reviews, 25-Oct-1999
  • Benzodiazepines for psychosis‐induced aggression or agitation
    Cochrane Systematic Reviews, 8-Dec-2017
  • Benzodiazepines for restless legs syndrome
    Cochrane Systematic Reviews, 20-Mar-2017
  • Benzodiazepines for schizophrenia
    Cochrane Systematic Reviews, 14-Nov-2012
  • Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults
    Cochrane Systematic Reviews, 20-Oct-2016
  • Benzodiazepines for treatment of patients with delirium excluding those who are cared for in an intensive care unit
    Cochrane Systematic Reviews, 28-Feb-2020
  • Benzodiazepines versus placebo for panic disorder in adults
    Cochrane Systematic Reviews, 28-Mar-2019
  • Benzo‐pyrones for reducing and controlling lymphoedema of the limbs
    Cochrane Systematic Reviews, 19-Apr-2004
  • Beta blockers for peripheral arterial disease
    Cochrane Systematic Reviews, 11-Sep-2013
  • Beta lactam antibiotic monotherapy versus beta lactam‐aminoglycoside antibiotic combination therapy for sepsis
    Cochrane Systematic Reviews, 7-Jan-2014
  • Beta radiation for glaucoma surgery
    Cochrane Systematic Reviews, 13-Jun-2012
  • Beta2-adrenoceptor agonists for dysmenorrhoea
    Cochrane Systematic Reviews, 19-Apr-2012
  • Beta2‐agonists for acute cough or a clinical diagnosis of acute bronchitis
    Cochrane Systematic Reviews, 3-Sep-2015
  • Beta2-agonists for exercise-induced asthma
    Cochrane Systematic Reviews, 26-Sep-2013
  • Beta-adrenergic blockers for perioperative cardiac risk reduction in people undergoing vascular surgery
    Cochrane Systematic Reviews, 12-Jan-2015
  • Beta-blocker supplementation of standard drug treatment for schizophrenia
    Cochrane Systematic Reviews, 15-Jun-2010
  • Beta‐blocker therapy for tremor in Parkinson's disease
    Cochrane Systematic Reviews, 20-Jan-2003
  • Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved ejection fraction
    Cochrane Systematic Reviews, 22-May-2021
  • Beta‐blockers for congestive heart failure in children
    Cochrane Systematic Reviews, 23-Jul-2020

Login or Subscribe


Not Yet a Subscriber?

Doctor with handheld

We offer subscriptions for individuals and institutions

To find out about all the benefits of a year-long subscription to Essential Evidence Plus, click the button below!

Learn More